Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele)

被引:20
作者
Moisan, J
Wojciechowski, W
Guilbault, C
Lachance, C
Di Marco, S
Skamene, E
Matlashewski, G
Radzioch, D
机构
[1] Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada
[2] McGill Univ, Dept Expt Med, Montreal, PQ, Canada
[3] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada
关键词
D O I
10.1128/AAC.45.11.3059-3064.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The mouse bcg host resistance gene is known to control the activation of host macrophages for killing of intracellular parasites like Leishmania donovani as well as intracellular bacteria, including Mycobacterium bovis BCG and Salmonella enterica serovar Typhimurium. The Nramp1 gene has been mapped to this locus and affects the efficiency of macrophage activation. It has been shown that imidazoquinoline compounds, including S28463, are able to improve the clearance of a number of intracellular pathogens such as herpes simplex virus 2, human papillomavirus, and Leishmania. The goal of this study was to determine whether S28463 is efficient against infection with another intracellular pathogen, M. bovis BCG, and to determine the molecular basis underlying this effect. To achieve this, B10A.Nramp1(r) and B10A.Nramp1(-/-) mice were infected with M. bovis BCG and treated with S28463. The bacterial content in the spleen from these mice was assayed by a colony-forming assay. In addition, in vitro experiments were performed using bone marrow-derived macrophage cell lines from these mice. These cells were treated with S28463 and/or gamma interferon (IFN-gamma), and nitric oxide (NO) production was measured. Our study was able to show that S28463 acts in synergy with IFN-gamma to increase the production of NO in vitro. We were also able to demonstrate that mice that carried the resistant allele of the Nramp1 gene and were infected with M. bovis BCG responded to treatment with S28463, resulting in a decreased bacterial load after 2 weeks of treatment. Mice that do not express the Nramp1 gene responded only to a very large dose of S28463, and the response was not as efficient as that observed in mice carrying a wild-type Nramp1 allele. Our data provide evidence for the potential of S28463 as an immunomodulator that may be helpful in designing efficient strategies to improve host defense against mycobacterial infection.
引用
收藏
页码:3059 / 3064
页数:6
相关论文
共 55 条
  • [1] Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848
    Ahonen, CL
    Gibson, SJ
    Smith, RM
    Pederson, LK
    Lindh, JM
    Tomai, MA
    Vasilakos, JP
    [J]. CELLULAR IMMUNOLOGY, 1999, 197 (01) : 62 - 72
  • [2] Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%
    Arany, I
    Tyring, SK
    Stanley, MA
    Tomai, MA
    Miller, RL
    Smith, MH
    McDermott, DJ
    Slade, HB
    [J]. ANTIVIRAL RESEARCH, 1999, 43 (01) : 55 - 63
  • [3] Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts
    Arany, I
    Tyring, SK
    Brysk, MM
    Stanley, MA
    Tomai, MA
    Miller, RL
    Smith, MH
    McDermott, DJ
    Slade, HB
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) : 1869 - 1873
  • [4] Atkinson BL, 1997, J CELL BIOCHEM, V65, P325, DOI 10.1002/(SICI)1097-4644(19970601)65:3<325::AID-JCB3>3.3.CO
  • [5] 2-G
  • [6] BARRERA LF, 1994, IMMUNOLOGY, V82, P457
  • [7] I-A beta gene expression regulation in macrophages derived from mice susceptible or resistant to infection with M-bovis BCG
    Barrera, LF
    Kramnik, I
    Skamene, E
    Radzioch, D
    [J]. MOLECULAR IMMUNOLOGY, 1997, 34 (04) : 343 - 355
  • [8] The natural resistance-associated macrophage protein and susceptibility to intracellular pathogens
    Bellamy, R
    [J]. MICROBES AND INFECTION, 1999, 1 (01) : 23 - 27
  • [9] ADJUVANT EFFECTS OF IMIQUIMOD ON A HERPES-SIMPLEX VIRUS TYPE-2 GLYCOPROTEIN VACCINE IN GUINEA-PIGS
    BERNSTEIN, DI
    MILLER, RL
    HARRISON, CJ
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (03) : 731 - 735
  • [10] EFFECTS OF THE IMMUNOMODULATING AGENT R837 ON ACUTE AND LATENT HERPES-SIMPLEX VIRUS TYPE-2 INFECTIONS
    BERNSTEIN, DI
    HARRISON, CJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) : 1511 - 1515